Prophase Labs (PRPH) Investor presentation summary

Cash recovery and restructuring

• Sold Pharmaloz Manufacturing for $23.6m in H1 2025; shut down the genomics lab, saving over $6m/year, and reduced IT services and headcount.

• Crown Medical is pursuing $50–$60m in net cash recovery over 12 months from COVID-19 receivables; litigation has begun and meet-and-confer discussions are underway.

• The effort addresses over $150m in uncollected receivables from more than 1,100 insurers; Crown’s compensation is contingent, with no upfront cost.

BE-Smart commercialization

• BE-Smart targets a $7–$14b market and is designed to analyze existing biopsy tissue, without requiring an additional patient sample after endoscopy.

• A validation study published in Clinical and Translational Gastroenterology supports clinical utility; brush-cytology testing achieved over 95% technical success, validating use with both brush and pinch biopsies.

• U.S. Patent No. 12,379,378-B2 protects esophageal adenocarcinoma risk assessment; commercialization planning includes a cash-based launch and potential strategic partnerships and payer coverage.

• Dr. Joe Abdo was appointed to drive commercialization; the Clinical Science Advisory Board includes Abdo and James McCullough.

Genomics and consumer products

• Nebula’s dataset spans 130 countries and totals 16 petabytes, equivalent to 150m ancestry SNP-based tests; its platform offers whole-genome sequencing and personalized reports.

• DNA Complete launched November 4, 2024, with whole-genome sequencing, 340+ personalized health predisposition reports, advanced ancestry analysis and encrypted data storage.

• DNA Complete offers $245, $595 and $1,295 tiers with 1x, 30x and 100x WGS, respectively; DNA Expand uses uploaded DNA data to expand coverage over 50x to more than 35m variants without new sequencing.